ArticleJournal of managed care & specialty pharmacy2024
A primer on brand-name prescription drug reimbursement in the United States.
Article in Journal of managed care & specialty pharmacy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- What should infectious diseases clinicians know about pharmacy benefit managers and their impact on our patients?Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Review
- Article
- A primer on prescription drug pricing benchmarks in the United States.Journal of managed care & specialty pharmacy · 2025Article
- Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association.The Lancet regional health. Europe · 2025Review
- Exploring the Lack of Transparency in Prescription Drug Costs: Contributors and Avenues for Reform.Journal of general internal medicine · 2025Article
- Advancing the conversation: 30 years of scholarship in managed care pharmacy.Journal of managed care & specialty pharmacy · 2025Article
- Assessment of Phosphorodiamidate Morpholino Oligomer Treatment Patterns for Patients with Duchenne Muscular Dystrophy: A MarketScan Claims Analysis.Advances in therapy · 2025Article
- Stakeholder insights on cost, quality, and incorporating patient voice in managed care decisions on neovascular (wet) age-related macular degeneration: Findings from the AMCP Market Insights program.Journal of managed care & specialty pharmacy · 2024Article
- Cheaper is not always better: Drug shortages in the United States and a value-based solution to alleviate them.Journal of managed care & specialty pharmacy · 2024Article
- A primer on brand-name prescription drug contracting.Journal of managed care & specialty pharmacy · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Branded prescription drug reimbursement in the United States is complex and comprises multiple transactions among the parties involved in the drug supply chain, including manufacturers, wholesalers, pharmacies, health care providers, health plans or insurers, pharmacy benefit managers, and patients. This primer provides an overview of the parties involved in the reimbursement of brand-name drugs under both the pharmacy and medical benefits of an insurance policy and the flow of products and payments among them. Prescription drug spending in the United States grew from $30 billion in 1980 to $335 billion in 2018, and 80% of spending is on brand-name drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.